Paratek Pharmaceuticals, Inc.
Compare this stock
PRTK Stock Report Card
$
45%
Performance
Score:
10/100
PRTK returned -12.00% in the last 12 months. Based on SPY's performance of -7.13%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
Score:
93/100
10 analysts offer 12-month price targets for PRTK. Together, they have an average target of 20, the most optimistic target put PRTK at 20 within 12-months and the most pessimistic has PRTK at 20. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).
Sentiment
Score:
69/100
PRTK had a bullish sentiment score of 69.17% across Twitter and StockTwits over the last 12 months. It had an average of 8.91 posts, 3.68 comments, and 7.87 likes per day.
Technicals
Score:
86/100
PRTK receives a 85 of 100 based on 14 indicators. 11 are bullish, 1 are bearish.
Earnings
Score:
10/100
PRTK has missed earnings 7 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, PRTK has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
49/100
PRTK has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
Paratek Pharmaceuticals, Inc. Summary
Nasdaq / PRTK
Healthcare
Biotechnology
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
PRTK scored poorly on our reportcard. Here are some similar companies and how they performed.
